ARS Pharmaceuticals (SPRY) announced the launch of “Get neffy on Us,” a new integrated commercial program to help patients access their needle-free epinephrine medicine, neffy. Get neffy on Us was created to eliminate the time burden of an in-person office visit by offering a free visit with a virtual provider who can prescribe neffy. Eligible patients with commercial insurance may have a $0 co-pay for neffy.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SPRY:
- ARS Pharmaceuticals resumed with a Buy at Roth Capital
- Ars Pharmaceuticals’ Latest Study: A Potential Game-Changer in Allergy Treatment
- Ars Pharmaceuticals’ Promising Study on ARS-2 for Chronic Urticaria: What Investors Need to Know
- ARS Pharmaceuticals receives favorable decision from EPO on neffy
- ARS Pharmaceuticals: Strategic Financial Maneuvers and Market Potential Drive Buy Rating